LAKES COMMUNITY CENTER 

WHERE NATURE IS YOUR NEIGHBOR

Important Dates

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Thursday - June 10

49er Committee Mtg. @LCC 7:00pm

Saturday- June 12

Chipping Day @LCC 9:00am - noon

SAFETY INFO
Check here for recent information on road closures, fires and weather updates.

CF101 drug fails to meet major efficacy endpoint in phase III study for Dry Eye Syndrome Can-Fite BioPharma Ltd. , , a biotechnology organization with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 sufferers with moderate-to-severe Dry Eyesight Syndrome who had been treated using its licensed drug CF101, an A3 adenosine receptor agonist cafergot in canada http://cafergot.net . The sufferers were randomized to get two oral dosages of CF101 or a placebo, for an interval of 24 weeks. In the scholarly study, CF101 do not meet the major efficacy endpoint of comprehensive clearing of corneal staining, nor the secondary efficacy endpoints.